Verona Pharma to Present at 43rd Annual Canaccord Growth Conference
26 juil. 2023 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., July 26, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona Pharma to Report Second Quarter 2023 Financial Results and Provide Corporate Update
20 juil. 2023 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., July 20, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona Pharma Announces Publication of Phase 3 ENHANCE Data in the American Journal of Respiratory and Critical Care Medicine
28 juin 2023 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., June 28, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces the American Journal of Respiratory and Critical Care...
Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD
27 juin 2023 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., June 27, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces the submission of a New Drug Application (“NDA”) to the US...
Verona Pharma to Present at Jefferies Healthcare Conference
24 mai 2023 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., May 24, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at...
Verona Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update
09 mai 2023 02h00 HE
|
Verona Pharma plc
NDA submission on schedule for Q2 2023 12 abstracts and one symposium expanding on successful Phase 3 ENHANCE data to be presented at American Thoracic Society 2023 Strong balance sheet to support...
Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023
02 mai 2023 02h00 HE
|
Verona Pharma plc
12 Abstracts and one Symposium further support potential of ensifentrine,a first-in-class, selective, dual inhibitor of PDE3 and PDE4 Conference call May 23 at 4:00 p.m. EDT / 9:00 p.m. BST LONDON...
Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update
25 avr. 2023 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., April 25, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD
10 avr. 2023 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., April 10, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
07 mars 2023 02h00 HE
|
Verona Pharma plc
Transformational results in Phase 3 ENHANCE program for COPD NDA submission expected Q2 2023 Strong balance sheet to support planned US commercial launch Conference call today at 9:00 a.m. EST /...